Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Other Accumulated Expenses (2019 - 2025)

VitaNova Life Sciences (YJGJ) has disclosed Other Accumulated Expenses for 5 consecutive years, with $3951.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 338.03% year-over-year to $3951.0, compared with a TTM value of $3951.0 through Oct 2025, up 338.03%, and an annual FY2025 reading of $820.0, down 90.12% over the prior year.
  • Other Accumulated Expenses was $3951.0 for Q4 2025 at VitaNova Life Sciences, up from $1226.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $28563.0 in Q2 2021 and bottomed at $820.0 in Q2 2025.
  • Average Other Accumulated Expenses over 3 years is $5713.1, with a median of $2795.0 recorded in 2025.
  • Peak annual rise in Other Accumulated Expenses hit 338.03% in 2025, while the deepest fall reached 90.12% in 2025.
  • Year by year, Other Accumulated Expenses stood at $28563.0 in 2021, then crashed by 96.84% to $902.0 in 2024, then surged by 338.03% to $3951.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for YJGJ at $3951.0 in Q4 2025, $1226.0 in Q3 2025, and $820.0 in Q2 2025.